TWST CEO files Form 4: 31,379 shares sold to cover taxes
Filing Impact
Filing Sentiment
Form Type
4
Rhea-AI Filing Summary
Twist Bioscience (TWST) CEO and director Emily M. Leproust reported a transaction on 10/30/2025: the disposition of 31,379 shares of common stock at $31.4443 per share. The filing states these shares were sold to cover tax withholding tied to the vesting of performance stock units, pursuant to the company’s equity plan “sell to cover” election, and were not discretionary trades.
Following the transaction, Leproust beneficially owns 738,809 common shares directly. Derivative holdings listed include employee stock options, such as 150,879 options at an exercise price of $8.82 and 266,539 options at $26.66, among others with varying vesting and expiration terms.
Positive
- None.
Negative
- None.
Insider Trade Summary
Net Seller: 31,379 shares ($986,691)
Net Sell
6 txns
Insider
Leproust Emily M.
Role
Chief Executive Officer
Sold
31,379 shs ($987K)
| Type | Security | Shares | Price | Value |
|---|---|---|---|---|
| Sale | Common Stock | 31,379 | $31.4443 | $987K |
| holding | Employee Stock Option (right to buy) | -- | -- | -- |
| holding | Employee Stock Option (right to buy) | -- | -- | -- |
| holding | Employee Stock Option (right to buy) | -- | -- | -- |
| holding | Employee Stock Option (right to buy) | -- | -- | -- |
| holding | Employee Stock Option (right to buy) | -- | -- | -- |
Holdings After Transaction:
Common Stock — 738,809 shares (Direct);
Employee Stock Option (right to buy) — 0 shares (Direct)
Footnotes (1)
- Represents the number of shares required to be sold by the Reporting Person to cover tax withholding obligations in connection with the vesting of Performance Stock Units ("PSUs"). These sales are mandated by the Issuer's election under its equity incentive plans to require the satisfaction of a tax withholding obligation to be funded by a "sell to cover" transaction and do not represent discretionary trades by the Reporting Person. The option is immediately exercisable. 25% of the shares subject to the option vested on September 1, 2016 and 1/48th of the shares subject to the option vest on each monthly anniversary thereafter, subject to the Reporting Person's continuous service through each vesting date. The option is immediately exercisable. 10% of the shares subject to the option vested on September 28, 2017, 15% of the shares subject to the option vested on September 28, 2018, and 1/48th of the shares subject to the option vest on each monthly anniversary thereafter, subject to the Reporting Person's continuous service through each vesting date. 20% of the shares subject to the option vested and became exercisable on October 31, 2019 and 1/60th of the shares subject to the option vest and become exercisable on each monthly anniversary thereafter, subject to the Reporting Person's continuous service through each vesting date. 25% of the shares subject to the option vested on October 24, 2020, and 1/48th of the shares subject to the option vest on each monthly anniversary thereafter, subject to the Reporting Person's continuous service through each vesting date. Represents performance stock options granted to the reporting person on September 1, 2020, that vested and became exercisable on December 19, 2022 as a result of the reporting person having met the applicable performance criteria.
FAQ
What insider transaction did TWST report?
Emily M. Leproust reported the sale of 31,379 TWST shares on 10/30/2025 at $31.4443 per share.
Were these TWST trades discretionary?
No. The filing states the sales were mandated by the issuer’s equity plan and were not discretionary trades.
What derivative securities are reported for the CEO at TWST?
Reported employee stock options include examples such as 150,879 at $8.82 and 266,539 at $26.66 exercise prices.
What is the role of the reporting person at Twist Bioscience (TWST)?
Emily M. Leproust is the Chief Executive Officer and a Director of TWST.